Has Tori Hord received payments from drug or device companies?

Yes. Drug and device makers reported $10,931 in general payments to Tori Hord across 531 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tori Hord did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tori Hord come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tori Hord

Nurse Practitioner · Slidell, LANPI 1336701069

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 531 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 31.4% of the total. Among nurse practitioner clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,931in general payments, 2019–2025

Across 531 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$3K
GSK$2K
Sanofi$1K
Regeneron Healthcare Solutions, Inc.$1K
Baxter Healthcare$520
Grifols USA, LLC$486
plus $2K from 21 others

What the payments were for

Food & beverage$10,931100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	129	$3,430
GSK	132	$2,030
Sanofi	50	$1,190
Regeneron Healthcare Solutions, Inc.	53	$1,070
Baxter Healthcare	22	$520
Grifols USA, LLC	22	$486
Boehringer Ingelheim	22	$418
Mylan Specialty L.p.	20	$374
Electromed, Inc.	23	$242
United Therapeutics Corporation	6	$133
Paratek Pharmaceuticals, Inc.	7	$124
Pfizer	8	$124
Merck	6	$123
ANI Pharmaceuticals, Inc.	4	$97
Amgen	4	$85
Viatris Specialty LLC	3	$75
Verona Pharma, Inc.	3	$69
Mallinckrodt Hospital Products Inc.	2	$59
Philips North America LLC	4	$58
Vifor Pharma, Inc.	2	$55
Actelion Pharmaceuticals US, Inc.	2	$44
Novartis	2	$36
Tactile Systems Technology Inc	1	$31
Insmed, Inc.	1	$19
Pulmonx Corporation	1	$13
Bayer	1	$13
Inogen, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,931 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana →

Medicare billing

Part B allowed, 2024

$15,835

Medicare patients

137

Services billed

215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	442	$397,005
Fasenra PenBenralizumab	17	$96,544
NucalaMepolizumab	20	$70,058
Dupixent PenDupilumab	15	$54,121
Dupixent SyringeDupilumab	12	$40,363
Breztri AerosphereBudesonide/Glycopyr/Formoterol	27	$27,227
Breo ElliptaFluticasone/Vilanterol	61	$25,308
Advair HfaFluticasone Propion/Salmeterol	21	$10,777
Albuterol Sulfate HfaAlbuterol Sulfate	288	$9,642
SymbicortBudesonide/Formoterol Fumarate	17	$7,618
Ventolin HfaAlbuterol Sulfate	53	$3,937
Arnuity ElliptaFluticasone Furoate	14	$3,500
Fluticasone-SalmeterolFluticasone Propion/Salmeterol	21	$1,810
Wixela InhubFluticasone Propion/Salmeterol	12	$1,660
Prednisone	127	$369

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta	$2,030	$495,870537 claims
AstraZenecaBreztri Aerosphere, Symbicort	$3,430	$34,84544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 969 nurse practitioner providers in Louisiana.